Buy IGF-1 LR3

Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid single-chain polypeptide that mediates the majority of GH's anabolic effects. Native IGF-1 circulates predominantly bound to IGF binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS), forming a ternary complex that restricts tissue distribution and limits receptor access. The bioavailable free fraction of native IGF-1 — the only fraction capable of binding the IGF-1 receptor (IGF-1R) — represents less than 1% of total circulating IGF-1. Furthermore, native IGF-1 has a plasma half-life of only 10–20 minutes in its unbound state due to rapid hepatic clearance and ubiquitous IGFBP sequestration. IGF-1 LR3 (Long Arg3 IGF-1) is a synthetic analogue incorporating two structural modifications that fundamentally alter its pharmacological behaviour. The first modification is the substitution of glutamic acid for arginine at position 3 (Arg3), which dramatically reduces IGFBP-3 affinity by approximately 1,000-fold compared to native IGF-1. The second modification is the addition of a 13-amino-acid N-terminal extension (the "Long" component) that further impairs binding protein interaction. Together, these changes extend the effective plasma half-life to 20–30 hours, compared to under 20 minutes for free native IGF-1, while preserving high-affinity binding to the IGF-1R tyrosine kinase receptor. Upon binding IGF-1R, IGF-1 LR3 induces receptor dimerisation and autophosphorylation of intracellular tyrosine residues (Tyr1158, Tyr1162, Tyr1163). This activates insulin receptor substrate 1 (IRS-1) and subsequent bifurcation into two major downstream cascades: the PI3K/Akt/mTORC1 pathway, which drives protein synthesis, ribosomal biogenesis, and inhibition of the ubiquitin-proteasome degradation system; and the Ras/Raf/MEK/ERK pathway, which promotes cell cycle progression, proliferation, and differentiation. In skeletal muscle, activated Akt phosphorylates FOXO transcription factors, suppressing atrogene expression (MuRF-1, MAFbx/atrogin-1) and tipping the protein turnover balance decisively toward net anabolism. The satellite cell activation pathway is particularly relevant for muscle hypertrophy. IGF-1 LR3 directly activates quiescent skeletal muscle satellite cells (muscle stem cells) — through IGF-1R-mediated upregulation of MyoD, myogenin, and other myogenic regulatory factors — causing satellite cell proliferation, differentiation, and fusion with existing myofibres. This mechanism increases myonuclear number, which expands the anabolic capacity of existing muscle fibres. Concomitantly, IGF-1 LR3 promotes nitrogen retention at the cellular level by stimulating amino acid transporter expression (SNAT2, LAT1) and increasing glutamine synthetase activity, reducing nitrogen excretion and improving whole-body protein balance.

IGF-1 LR3 is appropriate for experienced users with a thorough understanding of IGF-1 axis pharmacology who are seeking direct receptor-level anabolic stimulation rather than pituitary-mediated GH secretion. It is particularly relevant for individuals in post-cycle scenarios following anabolic cycles where endogenous IGF-1 production is suppressed, those seeking accelerated recovery from musculoskeletal injuries, or advanced physique athletes aiming to maximise lean tissue accretion. Due to the hypoglycaemia risk, it is not appropriate for beginners or individuals with diabetes, glucose dysregulation, or hepatic dysfunction. Sourcing criteria are stringent. IGF-1 LR3 requires sequence verification by mass spectrometry (confirming the correct 83-amino-acid sequence including the Arg3 substitution and N-terminal extension) in addition to HPLC purity confirmation above 98%. Incorrectly synthesised IGF-1 LR3 with sequence errors will not produce the intended IGFBP-evasion or receptor-binding profile and may carry unpredictable off-target activity. Vials must be lyophilised, sealed under inert atmosphere, and free of bacterial endotoxin (LAL testing certificate). Reconstitute with bacteriostatic water to no greater than 100 µg/mL concentration to maintain stability; use within four weeks of reconstitution when refrigerated. Dosing protocols typically used in research contexts range from 20 to 80 µg per day or every other day administered subcutaneously or intramuscularly, with cycles limited to four to six weeks to avoid receptor downregulation and to minimise cumulative dose-dependent risks. Post-workout administration capitalises on exercise-induced upregulation of IGF-1R and IRS-1 expression in muscle. Users should consume a carbohydrate-containing meal within 30 minutes of injection to blunt hypoglycaemia risk. IGF-1 blood testing before and after a cycle provides objective efficacy and safety monitoring.

Compared to GH secretagogue combinations such as CJC-1295/Ipamorelin, IGF-1 LR3 operates downstream and bypasses pituitary regulation entirely. Secretagogues work by stimulating the pituitary to produce more endogenous GH, which then drives hepatic IGF-1 production. IGF-1 LR3 skips this entire upstream cascade and directly activates IGF-1R throughout the body. This makes it more potent on a per-microgram basis for acute anabolic signalling but also removes the natural feedback safeguards that limit GH-mediated IGF-1 to physiological ranges. For users with pituitary dysfunction or who have maximised their endogenous GH output through secretagogue therapy, IGF-1 LR3 represents the logical next step. Compared to native recombinant IGF-1 (mecasermin/Increlex), IGF-1 LR3 is markedly more bioavailable due to its IGFBP resistance. Native IGF-1 administered systemically is rapidly sequestered by binding proteins, and only a small fraction reaches peripheral IGF-1R. The LR3 modification eliminates this limitation, producing pharmacologically relevant free IGF-1 concentrations at doses several-fold lower than those required with native IGF-1. Additionally, IGF-1 LR3's 20–30-hour half-life supports once-daily dosing, whereas native free IGF-1 would require multiple daily injections for equivalent receptor occupancy. For users comparing IGF-1 LR3 to des(1-3)IGF-1 — a competing N-terminal truncation — the LR3 variant offers superior duration of action while des(1-3)IGF-1 may offer slightly more CNS penetrance.